DelveInsight’s, “Advanced Hepatocellular Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Advanced Hepatocellular Carcinoma pipeline landscape. It covers the Advanced Hepatocellular Carcinoma pipeline drug profiles, including Advanced Hepatocellular Carcinoma clinical trials and nonclinical stage products. It also covers the Advanced Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report
- DelveInsight’s Advanced Hepatocellular Carcinoma Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Hepatocellular Carcinoma.
- The leading Advanced Hepatocellular Carcinoma Companies include CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
- Promising Advanced Hepatocellular Carcinoma Pipeline Therapies includes Enzalutamide, ABT-869, IBI308 200mg, Pembrolizumab/Quavonlimab, Lenvatinib, Cabozantinib, Sorafenib, INC280, Apatinib, Octreotide, and others.
- The Advanced Hepatocellular Carcinoma Companies and academics are working to assess challenges and seek opportunities that could influence Advanced Hepatocellular Carcinoma R&D. The Advanced Hepatocellular Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Advanced Hepatocellular Carcinoma.
Request a sample and discover the recent breakthroughs happening in the Advanced Hepatocellular Carcinoma Pipeline landscape @ Advanced Hepatocellular Carcinoma Pipeline Outlook
Advanced Hepatocellular Carcinoma Overview
Hepatocellular carcinoma (HCC) is an aggressive malignancy, resulting as the third cause of death by cancer each year. Unfortunately, considerable number of patients are diagnosed at advanced stage unsuitable for surgery or local treatment with poor prognosis and a median overall survival (OS) of about 6 months. Molecular targeted therapies have demonstrated promising efficacy in the management of cancer.
Recent Developmental Activities in the Advanced Hepatocellular Carcinoma Treatment Landscape
- Tivozanib is being evaluated in Phase I/II stage of clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.
- CS1003 is also unique in that it can simultaneously recognize human and mouse PD-1, which allows fast pre-clinical proof of concept for CS1003 in combination with novel targeted therapies using syngeneic mouse tumor models. Currently, the drug is being developed in Phase III stage of development for the treatment of advanced hepatocellular carcinoma.
- Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is an innovative PD-1 inhibitor with global quality standards jointly developed by Innovent and Eli Lilly and Company. Currently, the drug is being developed in Phase I stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.
For further information, refer to the detailed Advanced Hepatocellular Carcinoma Drugs Launch, Advanced Hepatocellular Carcinoma Developmental Activities, and Advanced Hepatocellular Carcinoma News, click here for Advanced Hepatocellular Carcinoma Ongoing Clinical Trial Analysis
Advanced Hepatocellular Carcinoma Emerging Drugs Profile
- Tivozanib : AVEO Oncology
FOTIVDA® (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models. Currently, Tivozanib is being evaluated in Phase I/II stage of clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.
- Nofazinlimab: CStone Pharmaceuticals
CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed for immunotherapy of various tumors. Compared to most of the monoclonal antibodies that bind human and monkey PD-1(either already approved or in clinical stage) , CS1003 demonstrates comparable high binding affinities across species against human, cynomolgus monkey and mouse PD-1, and is developed to disrupt the interaction of PD-1 with its ligands PD-L1 and PD-L2 .
- ECT 204: Eureka Therapeutics
ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer. Glypican 3 (GPC3) is a promising target for HCC therapies and is found in more than 70% of HCC cells. The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.
- Sintilimab: Eli Lilly and Company/Innovent
Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab worldwide, to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials.
Advanced Hepatocellular Carcinoma Pipeline Therapeutics Assessment
There are approx. 50+ key companies are developing therapies for Advanced Hepatocellular Carcinoma. The companies which have their Advanced Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include CStone Pharmaceuticals.
Find out more about the Advanced Hepatocellular Carcinoma Pipeline Segmentation, Therapeutics Assessment, and Advanced Hepatocellular Carcinoma Emerging Drugs @ Advanced Hepatocellular Carcinoma Treatment Landscape
Scope of the Advanced Hepatocellular Carcinoma Pipeline Report
- Coverage- Global
- Advanced Hepatocellular Carcinoma Companies- CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
- Advanced Hepatocellular Carcinoma Pipeline Therapies- Enzalutamide, ABT-869, IBI308 200mg, Pembrolizumab/Quavonlimab, Lenvatinib, Cabozantinib, Sorafenib, INC280, Apatinib, Octreotide, and others.
- Advanced Hepatocellular Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Advanced Hepatocellular Carcinoma Pipeline Companies and Therapies, click here @ Advanced Hepatocellular Carcinoma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Advanced Hepatocellular Carcinoma Executive Summary
- Advanced Hepatocellular Carcinoma: Overview
- Advanced Hepatocellular Carcinoma Pipeline Therapeutics
- Advanced Hepatocellular Carcinoma Pipeline Therapeutic Assessment
- Advanced Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Pre-Registration)
- Drug name : Company Name
- Drug profiles in the detailed report…..
- Last Stage Products (Phase III)
- Nofazinlimab: CStone Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/II)
- Tivozanib : AVEO Oncology
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Advanced Hepatocellular Carcinoma Key Companies
- Advanced Hepatocellular Carcinoma Key Products
- Advanced Hepatocellular Carcinoma – Unmet Needs
- Advanced Hepatocellular Carcinoma – Market Drivers and Barriers
- Advanced Hepatocellular Carcinoma – Future Perspectives and Conclusion
- Advanced Hepatocellular Carcinoma Analyst Views
- Advanced Hepatocellular Carcinoma Key Companies
- Appendix
Got Queries? Find out the related information on Advanced Hepatocellular Carcinoma Mergers and acquisitions, Advanced Hepatocellular Carcinoma Licensing Activities @ Advanced Hepatocellular Carcinoma Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services